- Home
- RFL vs DRRX Comparison
RFL vs DRRX Comparison
Compare RFL & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- DRRX
- Stock Information
- Founded
- RFL 2017
- DRRX 1998
- Country
- RFL United States
- DRRX United States
- Employees
- RFL N/A
- DRRX N/A
- Industry
- RFL Real Estate
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- DRRX Health Care
- Exchange
- RFL Nasdaq
- DRRX Nasdaq
- Market Cap
- RFL 54.4M
- DRRX 59.3M
- IPO Year
- RFL N/A
- DRRX 2000
- Fundamental
- Price
- RFL $1.34
- DRRX $1.91
- Analyst Decision
- RFL
- DRRX Hold
- Analyst Count
- RFL 0
- DRRX 1
- Target Price
- RFL N/A
- DRRX N/A
- AVG Volume (30 Days)
- RFL 110.9K
- DRRX 699.4K
- Earning Date
- RFL 11-05-2025
- DRRX 11-12-2025
- Dividend Yield
- RFL N/A
- DRRX N/A
- EPS Growth
- RFL N/A
- DRRX N/A
- EPS
- RFL N/A
- DRRX N/A
- Revenue
- RFL $732,000.00
- DRRX $1,657,000.00
- Revenue This Year
- RFL N/A
- DRRX N/A
- Revenue Next Year
- RFL N/A
- DRRX $673.00
- P/E Ratio
- RFL N/A
- DRRX N/A
- Revenue Growth
- RFL 35.56
- DRRX N/A
- 52 Week Low
- RFL $1.28
- DRRX $0.48
- 52 Week High
- RFL $3.19
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- RFL 38.86
- DRRX 67.35
- Support Level
- RFL $1.30
- DRRX $1.86
- Resistance Level
- RFL $1.51
- DRRX $1.97
- Average True Range (ATR)
- RFL 0.11
- DRRX 0.03
- MACD
- RFL -0.00
- DRRX -0.04
- Stochastic Oscillator
- RFL 12.90
- DRRX 14.29
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.